# A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07312188/  
OnCo record `nct07312188` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of F182112, Pomalidomide in multiple myeloma, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.

## Summary

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07312188 by Shandong New Time Pharmaceutical Co., LTD, with 90 participants planned, started 2025-07-02 and due to reach its primary completion in 2028-05-20. Interventions recorded: F182112+P, F182112+CD38. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07312188
- Phase: 2
- Setting: A Phase II Study of F182112 Combined With Different Administration Regimens in Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor: Shandong New Time Pharmaceutical Co., LTD
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07312188: https://clinicaltrials.gov/study/NCT07312188

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [F182112](https://onco.cc/drugs/f182112/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [Shandong New Time Pharmaceutical](https://onco.cc/companies/shandong-new-time-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07312188.json